Drug Type Small molecule drug |
Synonyms 6-(1-methyl-1h-pyrazol-4-yl)-1-((6-(1-methyl-1h-pyrazol-4-yl)imidazo(1,2-a)pyridin-3-yl)sulfonyl)-1h-pyrazolo(4,3-b)pyridine, Gumarontinib, Gumarontinib Hydrate + [5] |
Target |
Mechanism c-Met inhibitors(Hepatocyte growth factor receptor inhibitors) |
Therapeutic Areas |
Inactive Indication |
Originator Organization |
Inactive Organization- |
Drug Highest PhaseApproved |
First Approval Date CN (07 Mar 2023), |
RegulationOrphan Drug (US), Breakthrough Therapy (CN), Conditional marketing approval (CN), Priority Review (CN), Special Review Project (CN) |
Molecular FormulaC21H17N9O2S |
InChIKeyRYBLECYFLJXEJX-UHFFFAOYSA-N |
CAS Registry1642581-63-2 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | - | - |
Indication | Country/Location | Organization | Date |
---|---|---|---|
c-Met positive non-small cell lung cancer | JP | 24 Jun 2024 | |
MET Exon 14 Skipping Mutation Non-small Cell Lung Cancer | CN | 07 Mar 2023 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Non-Small Cell Lung Cancer | Phase 2 | US | 05 Nov 2020 | |
Non-Small Cell Lung Cancer | Phase 2 | US | 05 Nov 2020 | |
Non-Small Cell Lung Cancer | Phase 2 | JP | 05 Nov 2020 | |
Non-Small Cell Lung Cancer | Phase 2 | JP | 05 Nov 2020 | |
metastatic non-small cell lung cancer | Phase 2 | CN | 11 May 2020 | |
metastatic non-small cell lung cancer | Phase 2 | CN | 11 May 2020 | |
Recurrent Non-Small Cell Lung Cancer | Phase 2 | CN | 18 Nov 2019 | |
c-Met positive Adenocarcinoma of Esophagus | Phase 2 | CN | 31 Jul 2019 | |
c-Met positive Adenocarcinoma of Esophagus | Phase 2 | CN | 31 Jul 2019 | |
Advanced Lung Non-Small Cell Carcinoma | Phase 2 | US | 15 Jul 2019 |
Not Applicable | c-Met positive non-small cell lung cancer MET Overexpression | 32 | (pghyyjpcgw) = tnekdyatta fngbcunieu (hhmqerdwee, 63.6 - 92.8) View more | Positive | 01 Jan 2024 | ||
Phase 1/2 | 84 | Gumarontinib 300 mg | ckcenwdrhq(melthvztub) = 32/84, 38% ihosmudygo (yathhfpimz ) View more | - | 01 May 2023 | ||
Phase 1 | 32 | qfuqwfsvdb(qcneisdqfc) = jjelnvfxxj zkftbyysgz (qjjqkbbuzj, 21.1 - 56.3) View more | Positive | 03 Dec 2022 | |||
(treatment naïve patients) | qfuqwfsvdb(qcneisdqfc) = ihzofqxxjl zkftbyysgz (qjjqkbbuzj, 15.2 - 72.3) | ||||||
Phase 2 | 30 | cdpzjvicup(tunbqzsssr) = iwflwahxwu bcinicvucl (rdgharzjlt, [40.6 - 77.3]) View more | - | 03 Dec 2022 | |||
Phase 1 | 19 | yeyvlzdzsg(dcmhstzvqz) = nbusfcobka nppfyatdbz (orkqbufbdg ) View more | - | 01 Mar 2021 | |||
Phase 1 | 18 | gomsntzhit(owixuogiia) = Peripheral edema (n = 1, 5.5%), hypothyroidism (n = 1, 5.5%) oipztuapbf (eofjrnxxie ) View more | Positive | 25 May 2020 |